Oxidative damage in mild cognitive impairment and early Alzheimer's disease

Journal of Neuroscience Research

Volumn 85, Issue 14, 2007, Pages 3036-3040

  Lovell, Mark A ^a,b,c   Markesbery, William R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NONE   (United States)

Author keywords

Alzheimer's disease; DNA oxidation; Lipid peroxidation; Mild cognitive impairment; Oxidative damage; Protein oxidation; RNA oxidation

Indexed keywords

DEOXYRIBONUCLEOPROTEIN; REACTIVE OXYGEN METABOLITE;

ALZHEIMER DISEASE; BRAIN REGION; CLINICAL FEATURE; COGNITIVE DEFECT; DISEASE COURSE; HUMAN; LIPID PEROXIDATION; NERVE DEGENERATION; NEUROPATHOLOGY; OXIDATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY;

ALZHEIMER DISEASE; ANIMALS; COGNITION DISORDERS; HUMANS; LIPID PEROXIDATION; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 34648859471     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21346     Document Type: Short Survey

References (40)

1. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, Barnes LL, Fox JH, Bach J. 2002. Natural history of mild cognitive impairment in older persons. Neurology 59:198-205.
2. Butterfield DA, Reed T, Perluigi M, De Marco C, Coccia R, Cini C, Sultana R. 2006a. Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment. Neurosci Lett 397:170-173.
3. Butterfield DA, Poon HF, St. Clair D, Keller JN, Pierce WM, Klein JB, Markesbery WR. 2006b. Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol Dis 22:223-232.
4. Coyle JT, Puttfarcken P. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695.
5. DeCarli C. 2003. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol 2:15-21.
6. Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. 2005. Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci 25:9171-9175.
7. Engelhart MJ, Geerlings MI, Ruitenberg A, van Swieten JC, Hofman A, Witteman JC, Breteler MM. 2002. Dietary intake of antioxidants and risk of Alzheimer disease. JAMA 287:3223-3229.
8. Esterbauer H, Schaur RJ, Zollner H. 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11:81-128.
9. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, Taylor JO. 1989. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262:2551-2556.
10. Gomez-Ramos A, Diaz-Nido J, Smith MA, Perry G, Avila J. 2003. Effect of the lipid peroxidation product acrolein on tau phosphorylation in neural cells. J Neurosci Res 71:863-870.
11. Halliwell B, Gutteridge J. 1989. Free radicals in biology and medicine. New York: Oxford University Press.
12. Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 60:1119-1122.
13. Hofer T, Badouard C, Bajak E, Ravanat JL, Mattsson A, Cotgreave IA. 2005. Hydrogen peroxide causes greater oxidation in cellular RNA than in DNA. Biol Chem 386:333-337.
14. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, Markesbery WR. 2005. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64:1152-1156.
15. Liu Q, Smith MA, Avila J, DeBernardis J, Kansal M, Takeda A, Zhu X, Nunomura A, Honda K, Moreira PI, Oliveira CR, Santos MS, Shimohama S, Aliev G, de la Torre J, Ghanbari HA, Siedlak SL, Harris PL, Sayre LM, Perry G. 2005. Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radic Biol Med 38:746-754.
16. Markesbery WR, Ehmann WD. 1994. Trace element alterations in Alzheimer's disease. In: Terry RD, Katzman R, editors. Alzheimer's disease. New York: Raven Press.
17. Markesbery WR, Lovell MA. 2006. DNA oxidation in Alzheimer's disease. Antioxid Redox Signal 8:2039-2045.
18. Markesbery WR, Kryscio RJ, Lovell MA, Morrow JD. 2005. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment. Ann Neurol 58:730-735.
19. Markesbery WR, Schmitt FA, Kryscio RJ, Davis DG, Smith CD, Wekstein DR. 2006. Neuropathologic substrate of mild cognitive impairment. Arch Neurol 63:38-46.
20. Montine KS, Quinn JF, Zhang J, Fessel JP, Roberts LJ 2nd, Morrow JD, Montine TJ. 2004. Isoprostanes and related products of lipid peroxidation in neurodegenerative diseases. Chem Phys Lipids 128:117-124.
21. Montine TJ, Montine KS, McMahan W, Markesbery WR, Quinn JF, Morrow JD. 2005. F2-isoprostanes in Alzheimer and other neurodegenerative diseases. Antioxid Redox Signal 7:269-275.
22. Moreira PI, Honda K, Liu Q, Santos MS, Oliveira CR, Aliev G, Nunomura A, Zhu X, Smith MA, Perry G. 2005. Oxidative stress: the old enemy in Alzheimer's disease pathophysiology. Curr Alzheimer Res 2:403-408.
23. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. 1989. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 39:1159-1165.
24. Morris MC, Evans DA, Bienias JL, Tangney CC, Wilson RS. 2002. Vitamin E and cognitive decline in older persons. Arch Neurol 59:1125-1132.
25. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. 2001. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60:759-767.
26. Nunomura A, Chiba S, Lippa CF, Cras P, Kalaria RN, Takeda A, Honda K, Smith MA, Perry G. 2004. Neuronal RNA oxidation is a prominent feature of familial Alzheimer's disease. Neurobiol Dis 17:108-113.
27. Nunomura A, Honda K, Takeda A, Hirai K, Zhu X, Smith MA, Perry G. 2006. Oxidative damage to RNA in neurodegenerative diseases. J Biomed Biotechnol 2006:82323.
28. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303-308.
29. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, Galasko D, Jin S, Kaye J, Levey A, Pfeiffer E, Sano M, van Dyck CH, Thal LJ. 2005. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med (in press).
30. Picklo MJ, Montine TJ, Amarnath V, Neely MD. 2002. Carbonyl toxicology and Alzheimer's disease. Toxicol Appl Pharmacol 184:187-197.
31. Pratico D, Sung S. 2004. Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease. J Alzheimers Dis 6:171-175.
32. Selkoe DJ. 1991. The molecular pathology of Alzheimer's disease. Neuron 6:487-498.
33. St. George-Hyslop PH. 1994. The molecular genetics of Alzheimer's disease. In: Terry RD, Katzman R, Bick LL, editors. Alzheimer's disease. New York: Raven Press. p 345-352.
34. St. George-Hyslop PH, Tanzi RE, Polinsky RJ, Haines JL, Nee L, Watkins PC, Myers RH, Feldman RG, Pollen D, Drachman D, et al. 1987. The genetic defect causing familial Alzheimer's disease maps on chromosome 21. Science 235:885-890.
35. Sultana R, Perluigi M, Butterfield DA. 2006. Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics. Antiox Redox Signal 8:2021-2037.
36. Wallace DC. 1992. Mitochondrial genetics: a paradigm for aging and degenerative diseases? Science 256:628-632.
37. Wang J, Markesbery WR, Lovell MA. 2006. Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. J Neurochem 96:825-832.
38. Williams TI, Lynn BC, Markesbery WR, Lovell MA. 2006. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in mild cognitive impairment and early Alzheimer's disease. Neurobiol Aging 27:1094-1099.
39. Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D. 2005. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. Ann Neurol 58:623-626.
40. Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC. 2004. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 61:82-88.